BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics on the Road to Clinical Studies in
Parkinson's Disease
Tuesday August 14, 8:30 am ET
Company Reports Preliminary Results From Safety Supporting Study in
Primates
NEW YORK --(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc.
(OTCBB:BCLI - News), a leading developer of adult stem cell
technologies and therapeutics, is pleased to announce preliminary
results from its first safety supporting experiment. On February 8,
2007 in laboratories at the University of Navarra, Pamplona, Spain,
Prof. Jose Obeso transplanted the subject, a healthy monkey, with
BrainStorm's human bone marrow derived mesenchymal stem cells. The
stem cells had been induced to differentiate into neurotrophic
factor-producing cells, according to the protocol developed at the
Company's laboratories in Israel.
The monkey was treated daily with cyclosporine to prevent rejection
of the human originating cells by its immune system, and was
monitored for a variety of parameters for a period of three months.
Throughout this phase, the monkey appeared well and in good health,
with a usual appetite, and with no apparent change in physical and
behavioral parameters. Blood tests, an MRI of the monkey's brain and
an autopsy examination of the internal organs were also found to be
normal.
Additionally, brain tissues from the monkey were examined by Prof.
Jeffrey Kordower (Rush University, Chicago, USA). A few human
originating cells were detected in sections of the monkey's brain by
staining the sections with an antibody, which can distinguish
between the monkey's own brain cells and the human transplanted
cells. The human transplanted cells were surrounded by macrophages,
which may indicate a reaction of the monkey's immune system to the
transplanted human cells and their initial rejection. BrainStorm's
actual approach would involve autologous transplantation (i.e., the
use of the patient's own bone marrow-derived stem cells). With this
strategy, no rejection is expected and there will be no need to
suppress the immune system by medications that often cause severe
side effects.
"We are extremely pleased with the faster pace and direction in
which the Company is now moving," commented Chaim Lebovits,
President of BrainStorm. "The recent financing the Company has
received will, with G-d's help, allow BrainStorm to move forward
with the preparations necessary toward carrying out Phase I/II
clinical trials in patients with Parkinson's disease, and providing
the funding and support needed to conduct additional safety
pharmacology studies, such as toxicology."
Two additional normal monkeys recently underwent transplantation in
Pamplona with BrainStorm's human stem cells. The monkeys will also
be monitored for a period of three months for collection of
additional data; so far, the monkeys are in good health.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
